Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist Sitaxsentan

This publication has 14 references indexed in Scilit:

• Sitaxsentan Therapy for Pulmonary Arterial Hypertension
  American Journal of Respiratory and Critical Care Medicine, 2004
• Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist
  Clinical Pharmacokinetics, 2004
• Bosentan Therapy for Pulmonary Arterial Hypertension
  New England Journal of Medicine, 2002
• ET_A and ET_B Receptors Modulate the Proliferation of Human Pulmonary Artery Smooth Muscle Cells
  American Journal of Respiratory and Critical Care Medicine, 2002
• Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
  The Lancet, 2001
• Endothelin System: The Double-Edged Sword in Health and Disease
  Annual Review of Pharmacology and Toxicology, 2001
• Human Pulmonary Circulation Is an Important Site for Both Clearance and Production of Endothelin-1
  Circulation, 1996
• Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension
  New England Journal of Medicine, 1993
• Physiology and pharmacology of endothelins
  Medicinal Research Reviews, 1992
• Increased Plasma Endothelin-1 in Pulmonary Hypertension: Marker or Mediator of Disease?
  Annals of Internal Medicine, 1991